Overview
Safety Study in Patients With Scalp Psoriasis Suppression Following Maximal Use Treatment With Topical Product
Status:
Completed
Completed
Trial end date:
2018-01-02
2018-01-02
Target enrollment:
0
0
Participant gender:
All
All
Summary
An Open-Label, Safety Study to Assess the Potential for Adrenal Suppression Following Maximal Use DSXS topical product (Taro Pharmaceuticals U.S.A., Inc.) in Patients with Moderate to SevereScalp PsoriasisPhase:
Phase 2Accepts Healthy Volunteers?
Accepts Healthy VolunteersDetails
Lead Sponsor:
Taro Pharmaceuticals USA
Criteria
Inclusion Criteria:- Male or non-pregnant, non-lactating females 12-17 years of age.
Exclusion Criteria:
- Females who are pregnant, nursing, planning to become pregnant during the duration of
the study, or if of child-bearing potential and sexually active and not prepared to
use appropriate contraceptive methods to avoid pregnancy.